Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- HBV background: virus structure
- HBV host
- HBV background: prevention
- Universal vaccination: carriers (HBsAg)
- HBV vaccination
- Geographic distribution of HBV
- HBV transmission
- The ORFs of the HBV
- Mechanisms specific to HBV
- The immune reaction
- Virus cycle
- Chronic hepatitis B serology
- Interpretation of viral markers
- Natural history
- HBV natural history
- Hepatitis B: risk of becoming a carrier
- Immunotolerance
- Immune clearance (loss of tolerance)
- Asymptomatic carrier
- Goals of treatment
- Available treatments
- Treatment of HBV patients
- Use of medications: PEG IFN
- Use of medications: nucleoside/nucleotide analogs
- Resistance to antiviral treatment
- Resistance to antiviral treatment: What to do?
- Adefovir
- Mutants
- Predictors of complications
- Who requires HCC screening?
- Survival curves
- Conclusions
Topics Covered
- Virus structure and its genome
- Prevention: universal vaccination
- Geographic distribution
- HBV transmission
- Special HBV mechanisms
- The immune reaction and different phases
- Chronic hepatitis B serology
- Viral markers
- Risk of becoming a carrier
- Available treatments and their goals
- Medications
- Reistance to antiviral treatment
- Mutants
- HCC screening
- Survival
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Olivera-Martinez, M. (2017, January 31). Hepatitis B virus (HBV) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/UGNI5719.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Marco Olivera-Martinez has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Dr. Marco Antonio Olivera Martinez.
I am an Associate Professor
of Medicine
in the division
of Gastroenterology & Hepatology
at the University
of Nebraska Medical Center
in Omaha, Nebraska, United States.
I am the Associate Program Director
for the Transplant Hepatology
Fellowship.
0:22
So what we're gonna
talk about in this slide is
the structure
of the hepatitis B virus.
This virus is known
as being a DNA virus.
This is the only hepatotropic virus
that has DNA
in its genetic material.
It's known to be part of the family
of the hepadnavirus group.
The genome of this virus
is approximately 3.2 kilobases
and it has the ability
to conform particle of DNA
that is called cccDNA,
ccc standing for circular, close,
and covalent DNA.
The peculiarity of this portion
of genetic material
is that the virus can insert it
into the host's DNA
and from there,
its capability of producing
break for replication
once the patient develops
immunity to this agent.
There are eight known genotypes
of the hepatitis B virus
and they are classified
A, B, C, D, E, and H.
The antigens that we know
that the virus produces
are named s, e, and core.
The s antigen is known
as the surface antigen.
And this is the first particle
that is synthesized by the virus
as it confers the protection
in the surface of the variant,
so the virus can go
from cell to cell
or be alive in the blood stream.
The e and the core antigens
are particularly present
when the virus
is actively replicating.
From
the epidemiological standpoint,
240 million people
have chronic infection
by hepatitis B in the world.
Defining chronic hepatitis B
as a presence
of a positive surface antigen
for more than six months
according to the World Health
Organization definition.
And the prevention
of this infection
is carried out
by a recombinant vaccine
that is available worldwide.